Merck and AbbVie Are Facing Big Patent Cliffs, But Here's Why Both Are Still BuysThe Motley Fool • 07/03/23
For AbbVie's blockbuster Humira, cheaper competitors pose surprisingly little threat, analysts sayMarket Watch • 06/30/23